Acutus Medical, a Carlsbad, CA-based electrophysiology company focused on the development of medical technologies innovating the treatment of patients with complex cardiac arrhythmias, closed a $75m Series C financing.
The round included new investors Deerfield Management Company, Xeraya Capital, an undisclosed strategic investor as well as existing investors Advent Life Sciences, OrbiMed and GE Ventures.
The company intends to use the funds to continue to develop the entire suite of AcQMap products, expand its clinical programs worldwide and continue developing a U.S. and European sales force in preparation for commercialization in both geographies.
Led by Randy Werneth, president and chief executive officer, Acutus Medical is a global heart rhythm technology company that allows electrophysiologists (EPs) to diagnose and treat cardiac arrhythmias. Its AcQMap High Resolution Imaging and Mapping System maps Atrial fibrillation (AFIB) and other complex arrhythmias, identify the mechanism of those arrhythmias, and provide a guide for ablation therapy. In addition, it can show electrophysiologists the effectiveness of the therapy in real-time. After the ablation has been delivered and upon the next heartbeat, a new complete map is rendered to confirm how the therapy changed the electrical pattern inside the heart. This real-time feedback loop can continue until the electrophysiologist is satisfied that the therapy and the procedure have been successful.
The company is currently pursuing CE mark approval in Europe for the full suite of AcQMap™ System products.